US Stock MarketDetailed Quotes

VKTX Viking Therapeutics

Watchlist
  • 42.350
  • +0.030+0.07%
Close Dec 24 13:00 ET
  • 42.390
  • +0.040+0.09%
Post 16:56 ET
4.72BMarket Cap-45.05P/E (TTM)

Viking Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Viking Therapeutics Q3 2024 Earnings Date

Currency：USDOct 23, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
EPS
-0.25
-0.22
+0.03
Beat Est.
-8.13%
+4.35%
+11.50%
Net Income
--
-24.94M
--
-10.68%
Analyst Rating
Strong Buy

Dec 25, 2024

Viking Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 5 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Oct 23, 20242024/Q30.000 / 0.000--
Jul 24, 20242024/Q20.000 / 0.000--
Apr 24, 20242024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Oct 23, 20242024/Q30.000 / 0.000--
Jul 24, 20242024/Q20.000 / 0.000--
Apr 24, 20242024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

Viking Therapeutics Earnings Reports

  • Viking Therapeutics | 10-Q: Q3 2024 Earnings Report

    Oct 23 17:05 ET

  • Viking Therapeutics | 8-K: Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

    Oct 23 16:11 ET

  • Viking Therapeutics | 10-Q: Q2 2024 Earnings Report

    Jul 24 17:05 ET

  • Viking Therapeutics | 8-K: Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

    Jul 24 16:15 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Dec 25, 2024

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Price
    % Chg

    No Data

    Investment Theme Weight Loss Drugs
    Weight Loss Drugs
    Intraday-0.42%